全文获取类型
收费全文 | 651篇 |
免费 | 98篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 28篇 |
妇产科学 | 11篇 |
基础医学 | 183篇 |
口腔科学 | 7篇 |
临床医学 | 46篇 |
内科学 | 120篇 |
皮肤病学 | 18篇 |
神经病学 | 14篇 |
特种医学 | 72篇 |
外科学 | 42篇 |
综合类 | 19篇 |
一般理论 | 1篇 |
预防医学 | 38篇 |
眼科学 | 15篇 |
药学 | 11篇 |
中国医学 | 1篇 |
肿瘤学 | 127篇 |
出版年
2023年 | 5篇 |
2022年 | 9篇 |
2021年 | 7篇 |
2020年 | 13篇 |
2019年 | 9篇 |
2018年 | 8篇 |
2017年 | 8篇 |
2016年 | 13篇 |
2015年 | 9篇 |
2014年 | 21篇 |
2013年 | 19篇 |
2012年 | 15篇 |
2011年 | 17篇 |
2010年 | 23篇 |
2009年 | 30篇 |
2008年 | 21篇 |
2007年 | 19篇 |
2006年 | 19篇 |
2005年 | 20篇 |
2004年 | 14篇 |
2003年 | 24篇 |
2002年 | 23篇 |
2001年 | 22篇 |
2000年 | 28篇 |
1999年 | 18篇 |
1998年 | 28篇 |
1997年 | 21篇 |
1996年 | 27篇 |
1995年 | 21篇 |
1994年 | 19篇 |
1993年 | 24篇 |
1992年 | 22篇 |
1991年 | 6篇 |
1990年 | 14篇 |
1989年 | 13篇 |
1988年 | 27篇 |
1987年 | 22篇 |
1986年 | 22篇 |
1985年 | 21篇 |
1984年 | 7篇 |
1983年 | 8篇 |
1982年 | 8篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1975年 | 5篇 |
1974年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有755条查询结果,搜索用时 15 毫秒
61.
Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer 总被引:17,自引:0,他引:17
Koukourakis MI Giatromanolaki A Thorpe PE Brekken RA Sivridis E Kakolyris S Georgoulias V Gatter KC Harris AL 《Cancer research》2000,60(11):3088-3095
Vascular endothelial growth factor (VEGF) is an important angiogenic factor, linked to poor outcome in human malignancies including non-small cell lung carcinoma (NSCLC). We used the 11B5 monoclonal antibody recognizing the VEGF/KDR complex (R. A. Brekken et al., Cancer Res., 58: 1952-1959, 1998) to assess the VEGF expression in cancer cells and the VEGF/KDR activated microvessel density (aMVD) in early operable NSCLC. The JC70 anti-CD31 monoclonal antibody was used to assess the standard MVD (sMVD). The aMVD was significantly higher in the invading front of the tumors and in the normal lung adjacent to the tumors as compared with normal lung distant to the tumor or to inner tumor areas (P < 0.0002). The sMVD was higher in the normal lung and decreased from the invading front to inner tumor areas (P < 0.0001). However, the vascular activation (aMVD:sMVD) was 4-6 times higher in the tumor areas as compared with lung from normal individuals (36-58% versus 9%; P < 0.0001). Fibroblast 11B5 reactivity, noted in 25% of cases, correlated with high aMVD and sMVD in the inner tumor areas. Multivariate analysis showed that aMVD was the most potent and independent prognostic factor (P = 0.001; t-ratio, 3.28). It is concluded that intense VEGF/KDR angiogenic pathway activation is a tumor-specific feature in more than 50% of NSCLC cases and is associated with poor postoperative outcome. Clinical trials involving targeting of the VEGF/KDR-positive vasculature with specific antibodies, such as 11B5, are, therefore, encouraged. 相似文献
62.
Giatromanolaki A Koukourakis MI Stathopoulos GP Kapsoritakis A Paspatis G Kakolyris S Sivridis E Georgoulias V Harris AL Gatter KC 《Oncology research》2000,12(1):33-41
The assessment of the angiogenic profile of tumors may become an important tool as a guide for the inclusion of novel drugs and molecular therapies into the standard chemoradiotherapy policy. Several studies have shown the prognostic importance of microvessel density (MVD) and of angiogenic factor expression in operable gastric cancer. In the present study we investigated, with immunohistochemistry the MVD, the expression of vascular endothelial growth factor (VEGF) and of thymidine phosphorylase (TP) expression, as well as the nuclear expression of p53 protein, in a series of patients with locally advanced inoperable gastric cancer. A strong association of VEGF with TP expression was noted (P = 0.005), and tumors coexpressing these factors had a statistically higher MVD (P = 0.0001). Nuclear p53 accumulation was also related to a high MVD (P = 0.004), and this was independent of VEGF or TP expression. Microvessel density showed a bell-shaped association with prognosis; cases with an intermediate MVD exhibit a favorable outcome (P < 0.05). A trend of nuclear TP expression to define a group of patients with poorer prognosis was noted (P = 0.06), while none of the remaining variables showed any significant association. The immunostaining results allowed the grouping of the angiogenic profile in four major categories: 1) highly vascularized tumors with VEGF and/or TP expression (about 36% of cases); 2) highly angiogenic tumors with p53 nuclear accumulation and low VEGF/TP expression (7% of cases); 3) poorly vascularized tumor with low VEGF/TP and negative nuclear p53 staining (32% of cases); 4) poorly vascularized tumors with TP expression (7% of cases). Specific therapies targeting hypoxia, VEGF, or TP expression as well as p53 gene therapy have entered clinical experimentation or are already available for clinical use. Using the suggested markers more than 80% of locally advanced gastric carcinomas can be grouped in different categories according to their angiogenic profile. Such a categorization may be useful for phase III trials on novel therapies targeting the major angiogenesis-related features studied here. 相似文献
63.
64.
Computed tomographic appearance of the bulging annulus 总被引:6,自引:0,他引:6
65.
66.
Stewart M Turley H Cook N Pezzella F Pillai G Ogilvie D Cartlidge S Paterson D Copley C Kendrew J Barnes C Harris AL Gatter KC 《Histopathology》2003,43(1):33-39
AIMS: Angiogenesis is an important factor in tumour growth and metastasis. Vascular endothelial growth factor receptor 2 (VEGFR-2) or KDR plays a crucial role in angiogenesis. The aim of this study was to raise and characterize antibodies against phosphorylated KDR which could be used for studies on human tissues to assess KDR activation and novel inhibitors of KDR activation in clinical trials. METHODS AND RESULTS: Three monoclonal antibodies and one rabbit polyclonal antiserum were produced. The specificity of the antibodies was confirmed by ELISA. One of the mouse antibodies and the rabbit polyclonal antiserum reacted with a 200-kDa band on a Western blot of human umbilical vein endothelial cell (HUVEC) lysates, the molecular weight of KDR. Immunohistochemical staining showed that phosphorylated KDR is present in a wide variety of normal tissues including liver, colon and placenta, and is not restricted to endothelium. It was also present in a number of human tumours including breast carcinomas, colonic carcinomas and non-Hodgkin's lymphomas. The pattern of staining was membranous, cytoplasmic and nuclear. CONCLUSIONS: This study has shown that phosphorylated KDR is present in a wide variety of tumour and tissue types and is not confined to endothelium. 相似文献
67.
68.
MacLean AB Reid WM Rolfe KJ Gammell SJ Pugh HE Gatter KC Wong Te Fong AC Crow JC Perrett CW 《The Journal of reproductive medicine》2000,45(8):609-612
OBJECTIVE: To investigate the presence of angiogenic factors in benign, premalignant and malignant vulvar lesions. STUDY DESIGN: Immunohistochemical demonstration of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PD-ECGF) in normal vulvar skin, lichen sclerosus, vulvar intraepithelial neoplasia (VIN) and vulvar cancer. RESULTS: VEGF was found in the majority of vulvar cancers but only a minority of VIN lesions. PD-ECGF was found in the majority of lesions. CONCLUSION: Demonstration of angiogenesis may suggest which preinvasive lesions will progress to invasive cancer. 相似文献
69.
Stenosis of the vena cava: preliminary assessment of treatment with expandable metallic stents 总被引:11,自引:0,他引:11
Charnsangavej C; Carrasco CH; Wallace S; Wright KC; Ogawa K; Richli W; Gianturco C 《Radiology》1986,161(2):295-298
To test the ability of Gianturco expandable metallic stents to dilate and maintain patency in stenotic venae cavae, stenosis of the inferior vena cava was created in seven mongrel dogs by the percutaneous injection of absolute ethanol into the paravascular retroperitoneal space. Gianturco stents, placed across the stenotic segment, resulted in successful dilatation with improved hemodynamics in four dogs. The stents failed to dilate an occluded vena cava in one dog; in the remaining dogs, stent placement was complicated by early migration and occlusion. Gianturco stents were placed in two patients, one with superior vena cava syndrome and one with retroperitoneal fibrosis that obstructed the inferior vena cava, and resulted in immediate relief of presenting symptoms. These results should be viewed cautiously, but further investigation into the clinical use of the stents is indicated, especially for patients for whom other treatments are difficult. 相似文献
70.
A new monoclonal antibody (KB61) recognizing a novel antigen which is selectively expressed on a subpopulation of human B lymphocytes. 总被引:4,自引:0,他引:4
下载免费PDF全文
![点击此处可从《Immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
K Pulford E Ralfkiaer S M MacDonald W N Erber B Falini K C Gatter D Y Mason 《Immunology》1986,57(1):71-76
The present paper describes a new monoclonal antibody (KB61) raised against hairy cell leukaemia cells. Antibody KB61 recognizes a molecule of approximately 40,000 molecular weight on human B cells. It reacts with B lymphocytes in the peripheral blood, in primary lymphoid follicles, in the mantle zone of secondary follicles, in interfollicular areas and in splenic marginal zone areas. However, germinal centre lymphoid cells do not express the antigen recognized by antibody KB61. The antibody shows limited reactivity outside the lymphoid system, i.e. polymorphs, tissue macrophages endothelial cells in the hepatic sinusoids. Antibody KB61 discriminates between different types of B-cell malignancies, reacting with the neoplastic cells in hairy cell leukaemia, chronic lymphocytic leukaemia (of B-cell type), prolymphocytic leukaemia and centrocytic lymphoma, but not with acute lymphoblastic leukaemia, germinal centre-derived lymphomas (other than centrocytic), Burkitt's lymphoma and lymphoblastic lymphoma. Antibody KB61 may be of value in the study of B-cell subpopulations and in the differential diagnosis of B-cell neoplasms. 相似文献